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Abstract
Introduction: Systemic lupus erythematosus (SLE) is a 
prototypic systemic autoimmune disease characterized 
by various immunological abnormalities, including 
dysregulated activation of both T and B lymphocytes. 
The etiology of this immunological disorder has not been 
clearly elucidated. Aberrant production and imbalance 
of T-helper (Th) cell cytokines have been implicated in 
the pathogenesis of autoimmunity. The aim of this study 
is to evaluate the level of Th1 cytokines interleukin-18 
(IL-18) and osteopontin (OPN) in SLE patients and their 
correlation with the disease activity. 
Methods: The study included 24 patients with SLE and 
20 age- and sex- matched control subjects. The disease 
activity was evaluated with the SLE disease activity 
index (SLEDAI). Plasma OPN and IL-18 concentrations 
were measured in patients and control groups using an 
enzyme linked immunosorbent assay. 
Results: Plasma OPN and IL-18 concentrations were 
significantly higher in SLE patients than in the control 
group (P < 0.001). OPN and IL-18 concentrations 
correlated positively and significantly with SLEDAI 
scores in SLE patients (r = 0.831, P < 0.001 and r = 0.826, 
P < 0.001 respectively). In addition, there was a highly 
significant positive correlation between OPN and IL-18 
levels (r = 0.75, P < 0.001). 
Conclusion: The circulating IL-18 and OPN concentrations 
were significantly elevated in SLE patients and correlated 
with the SLEDAI score. This suggests a crucial role 
for Th1 cytokines in the inflammatory processes and 
tissue damage in SLE disease. Both cytokines my act as 
potential disease markers for monitoring of SLE disease 
activity and therapeutic efficacy.
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Introduction 
Systemic lupus erythematosus (SLE) is a prototypic 
systemic autoimmune disease characterized by various 
immunological abnormalities, including dysregulated 
activation of both T and B lymphocytes with the 
production of a large quantity of auto-reactive antibodies 
and the formation of immune complexes causing tissue 
and organ damage [1-2]. In some patients, skin rash and 
joint pain predominate , while in others glomerulonephritis 
is the main lesion [2]. The etiology and pathogenic 
mechanism of this immunological disorder have not been 
clearly elucidated. Aberrant production and imbalance of 
T-helper (Th) cell cytokines have been implicated in the 
pathogenesis of autoimmunity [3].
Wong et al demonstrated that the plasma concentration 
of proinflammatory cytokine interleukin-18 (IL-18) 
was significantly elevated in SLE patients compared 
to controls [4]. IL-18 is a pro-inflammatory cytokine, 
predominantly released by antigen presenting cells such 
as macrophages and dendritic cells. IL-18 acts as a Th1 
cytokine since it promotes both proliferation of Th1 
lymphocytes and IFN-gamma production by these cells 
[5]. It plays an important role in innate immunity and 
shares functional similarities with IL-12 which induces 
the production of IL-18 by activation of natural killer 
cells (NK) and cytotoxic T lymphocytes (CTL) [6].
Human IL-receptor protein is a functional component of 
IL-18 receptors. IL-18 receptors are selectively expressed 
on murine Th1 cells but not Th2 cells [7]. The primary 
function of IL-18 includes the induction of IFN-gamma 
and TNF-alpha in T cells and NK cells, the up-regulation 
of Th1 cytokines, including IL-2, granulocytes-
macrophage colony stimulating factor (GM-CSF) and 
IFN-gamma, stimulation of proliferation of activated T 
cells and the enhancement of Fas ligand expression in 
NK cells and CTL [7].
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Osteopontin (OPN) is a phosphorylated glycoprotein 
secreted by the activated macrophages, leukocytes and 
activated T lymphocytes. It is present in extra cellular 
fluids, at sites of inflammation, and in the extra cellular 
matrix of mineralized tissues [8]. 
During inflammation, OPN is expressed by cells of 
both innate and adaptive immunity, such as NK cells, 
activated T cells, macrophages and resident fibroblasts 
[9]. OPN is also called early T-lymphocyte activation 
protein 1 (Eta-1) because of its early production upon 
cell activation, and has been shown to enhance Th1 but 
inhibit Th2 response [10].
Among multiple receptors for OPN, CD44 is the most 
characterized receptor that appears to mediate the cell 
chemotaxis [11]. Also, it plays various biological roles 
for host defense, bone formation, osteoclast activation 
and wound healing [12]. Its cytokine activities include 
the stimulation of macrophage and T-cell migration [12], 
protection against herpes viruses and bacterial infections 
through the activation of the Th1 response [10], and 
induction of Th1-cell-mediated autoimmunity [8].
Increased plasma concentration, protein expression 
and local production of OPN have been observed in 
sepsis [13], metastasis [14], multiple sclerosis [15], 
autoimmune/lymphoproliferative syndrome [16], renal 
tissue of SLE patients [17] and rheumatoid joints of 
patients with rheumatoid arthritis [18]. However, the 
circulating level and ex vivo production of OPN in SLE 
patients and its correlation with disease severity has not 
been well defined [19].
The aim of this work is to study the level of Th1 cytokine 
Interleukin-18 (IL-18) and Oseteopontin (OPN) in SLE 
patients and to study its possible correlation with disease 
activity.
Methods
The present study was carried out in the Renal and 
Vasculitis unit in University Hospital Birmingham, UK, 
on 24 SLE patients and 20 matched controls. The studied 
groups were subjected to full history taking, general 
examination, clinical activity scoring, routine laboratory 
analysis (ESR, CBC, ANA) and urine analysis. Their 
disease activity was evaluated with the SLE disease 
activity index (SLEDAI) [20]. The score comprises 
24 weighted components grouped into four categories, 
evaluated over a time frame of 10 days (Table 1). 
Change in SLEDAI score of three points or more to a 
level of eight or more indicates mild to moderate flare or 
persistent disease activity. Change in SLEDAI score of 
twelve points or more indicates severe flare. 
Twenty millimeters of EDTA preserved venous peripheral 
blood were collected from each patients and control 
subject, samples were preserved at -70° until used for 
cytokine assay. 
Measurement of IL-18 was done using the human 
bioactive IL-18 ELISA kit of medical biological 
laboratories (Nagoya, Japan), code No 7620, according 
to the manufacturer’s instructions. The human IL-18 
ELISA kit measures human IL-18 by sandwich ELISA. 
The assay uses two monoclonal antibodies against two 
different epitopes of human IL-18.
Quantification of OPN was done using enzyme 
immunometric assay kit, assay design MI, USA (Catalog 
No. 900-142). The kit uses two monoclonal antibodies to 
human OPN; one is immobilized on a microtiter plate to 
Table 1: SLE disease activity index (SLEDAI) 
Score Item
8 Seizure, psychosis, organic brain syndrome, visual disturbance, cranial nerve disorder, lupus headache, CVA, vasculitis 
4 Arthritis, myositis, urinary casts, hematuria, proteinuria, and pyuria
2 Rash, alopecia, mucosal ulcers, pleurisy, pericarditis, low complement, high DNA 
1 Fever, low platelets, low WBC
Table 2: Patients' laboratory and demographic data 
Patient characteristic Range Mean ± SD
Age 14 – 50 years 26.9 ± 8.4 years
Duration of disease 6 months to 10 years 3.4 ± 1.7 years
S. Creatinine 0.8 - 1.6 mg/dl 1.2 ± 0.19 mg/dl
SLEDAI Score 4 – 30 17.5 ± 7.7
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bind human OPN in the standards or samples. The other 
antibody is a biotinylated monoclonal antibody to human 
OPN. The manufactures instructions were followed and 
OPN concentration in the samples was determined by 
interpolation from standard curve.
Statistical analysis was done using Statistical Package 
for Social Science version 10.0 for Windows (SPSS, 
Inc., Chicago, IL, USA).  The data were presented in the 
form of mean + standard deviation (SD). Student (t) test 
was used for comparison of quantitative data. Spearman 
Rank correlation coefficient was done to study the 
relation between variables in each group. Significance 
was considered when P value was less than 0.05.
Results
The SLE group consisted of 20 females and four males; 
their age ranged from 14-50 years with a mean value 
of 26.9 ± 8.4 years. The duration of the disease ranged 
from 6 months to 10 years with a mean value of 3.4 ± 
1.7 years (Table 2). The diagnosis of SLE was according 
to the 1982 revised American Rheumatism Association 
Criteria [21].
The control group consisted of 15 females and five males; 
their age ranged from 15 - 50 years with a mean value of 
27.1 ± 8.6 years.
The concentration of cytokine IL-18 was significantly 
higher in SLE patients than the control group (471.1±140.2 
versus 155.4±35.7 pg/ml, P < 0.001) (Figure 1). There 
was also significant correlation between plasma IL-18 
concentrations and SLE disease activity score (r = 0.826, 
P < 0.001).
The concentration of OPN was significantly higher in 
SLE patients than control group (483.33±118.35 versus 
350±67.67 ng/ml, P < 0.001) (Figure 2). There was also 
highly significant correlation between plasma OPN and 
SLE disease activity (r = 0.831, P < 0.001) (Figure 3).
In addition, there was a highly significant positive 
correlation between plasma levels of OPN and IL-18 (r = 
0.75, P < 0.001).
Discussion
SLE has been postulated to be an autoantibody, immune 
complex and Th2 cytokine mediated disease [22]. 
However, previous studies have reported different results 
for the correlation of the Th1/Th2 ratio with SLE disease 
activity. One study showed a positive and significant 
correlation of this ratio with SLEDAI score using in vitro-
stimulated peripheral blood mononeuclear cells (PBMC) 
[23]. Another study reported a negative correlation 
between the ratio of IFN-alpha/IL-10 secreting cells 
and disease activity as measured by enzyme-linked 
immunospot analysis of freshly isolated PBMC [24]. 
Animal experiments using autoimmune mice found that 
the ratio of Th1/Th2 cytokine mRNA expression of IL-2 
and IL-4, IFN-alpha and IL-10 in polymorphonuclear 
neutrophils and PBMC exhibited a reciprocal relationship 
with disease severity [25]. However, several clinical 
studies have indicated that elevation in Th1 cytokines, 
including IL-12 [26], TNF-alpha [27] and IFN-gamma 
[28] can mediate the inflammatory processes that lead to 
Figure 1: Plasma IL-18 concentration in SLE patients and 
controls
Figure 2: Plasma OPN concentration in SLE patients and 
controls 
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irreversible organ damage, such as renal failure in SLE 
[29]. Chan et al reported that patients with active lupus 
nephritis have a predominant Th1 type of T-lymphocyte 
activation [30].
IL-18 is a proinflammatory cytokine related to the IL-1 
family. It plays an important role in innate immunity 
and Th1 response to toxic shock, and shares functional 
similarities with IL-12 [6]. Wong et al reported 
significantly elevated IL-18 concentration in SLE patients 
compared with control [31]. These results suggest that Th1 
predominance is important in SLE disease development. 
OPN is a cytokine that has been newly implicated in 
autoimmunity and other inflammatory processes [22].
We measured both IL-18 and OPN cytokine level in SLE 
patients to  correlate it with the disease activity.
In this study, the plasma concentration of the Th1 
cytokine IL-18 was significantly elevated in SLE patients 
compared to control, and this elevation was positively 
correlated to SLEDAI. These results are in agreement 
with other reports [32] which proposed that IL-18 can 
enhance the expression of Fas ligand in NK cells and 
CTL, causing Fas-mediated apoptosis in epithelial cells 
and tissue damage. Moreover, IL-18 in combination with 
other pro-inflammatory cytokines, including IL-1 and 
TNF-alpha may be important cytokines for the initiation 
and progression of catabolic response and fever in SLE 
[5].
In contrast to those results, Robak et al found no 
difference in the levels of IL-18 between active and 
inactive SLE [33]. This may be explained by the fact 
that SLE is a heterogeneous disease in which variability 
in the mean levels of certain cytokines is expected. In 
addition, cytokines level in the plasma may not reflect the 
locally high concentration produced in lymphoid tissues. 
Cytokines in the plasma may be bound to proteins or form 
complexes with soluble receptors or auto antibodies, 
which may affect their detection [34].
In this study, the plasma concentration of the cytokine 
OPN was significantly increased in SLE patients 
compared to controls, and correlated positively with 
SLEDAI. Moreover, it was significantly and positively 
correlated with the plasma concentration of IL-18 in SLE 
patients. These findings concur with the findings reported 
by Wong et al [32].  
In conjunction with the inflammatory activities of 
IL-18, such as the induction of Th1 cytokine IFN-alpha 
and activation of T cells, NK cells and cytotoxic T 
lymphocytes [35], OPN can enhance the Th1-mediated 
inflammatory process, activation of NK and T cells, and 
macrophage migration during an exacerbation of SLE. 
Figure 3: Correlation between plasma OPN level and SLEDAI score
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Acting together with other pro-inflammatory cytokines, 
including IL-1 and TNF-alpha, OPN may be an important 
cytokine for initiating and perpetuating the Th1 immune 
response and renal derangement in SLE.
Apart from Th1-cell activation, OPN can also activate 
macrophage adhesion [36], migration [30] and cytokine 
release [10]. Our present findings therefore support the 
attribution of increased ex-vivo production of OPN to the 
activation of macrophages and T cells in the inflammatory 
process during SLE exacerbation.
Conclusion
This study confirms the association between the 
production of OPN and IL-18 and SLE disease activity. 
This suggests a crucial role for the Th1 cytokines in 
the inflammatory processes and tissue damage in SLE 
disease. In view of these results, OPN and IL-18 may 
also serve as potential markers for monitoring of SLE 
disease activity and therapeutic efficacy.
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